Show simple item record

dc.contributor.authorAbraham, SA
dc.contributor.authorHopcroft, LEM
dc.contributor.authorCarrick, E
dc.contributor.authorDrotar, ME
dc.contributor.authorDunn, K
dc.contributor.authorWilliamson, AJK
dc.contributor.authorKorfi, K
dc.contributor.authorBaquero, P
dc.contributor.authorPark, LE
dc.contributor.authorScott, MT
dc.contributor.authorPellicano, F
dc.contributor.authorPierce, A
dc.contributor.authorCopland, M
dc.contributor.authorNourse, C
dc.contributor.authorGrimmond, SM
dc.contributor.authorVetrie, D
dc.contributor.authorWhetton, AD
dc.contributor.authorHolyoake, TL
dc.date.accessioned2021-04-22T01:27:06Z
dc.date.available2021-04-22T01:27:06Z
dc.date.issued2016-06-16
dc.identifierpii: nature18288
dc.identifier.citationAbraham, S. A., Hopcroft, L. E. M., Carrick, E., Drotar, M. E., Dunn, K., Williamson, A. J. K., Korfi, K., Baquero, P., Park, L. E., Scott, M. T., Pellicano, F., Pierce, A., Copland, M., Nourse, C., Grimmond, S. M., Vetrie, D., Whetton, A. D. & Holyoake, T. L. (2016). Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. NATURE, 534 (7607), pp.341-+. https://doi.org/10.1038/nature18288.
dc.identifier.issn0028-0836
dc.identifier.urihttp://hdl.handle.net/11343/269248
dc.description.abstractChronic myeloid leukaemia (CML) arises after transformation of a haemopoietic stem cell (HSC) by the protein-tyrosine kinase BCR-ABL. Direct inhibition of BCR-ABL kinase has revolutionized disease management, but fails to eradicate leukaemic stem cells (LSCs), which maintain CML. LSCs are independent of BCR-ABL for survival, providing a rationale for identifying and targeting kinase-independent pathways. Here we show--using proteomics, transcriptomics and network analyses--that in human LSCs, aberrantly expressed proteins, in both imatinib-responder and non-responder patients, are modulated in concert with p53 (also known as TP53) and c-MYC regulation. Perturbation of both p53 and c-MYC, and not BCR-ABL itself, leads to synergistic cell kill, differentiation, and near elimination of transplantable human LSCs in mice, while sparing normal HSCs. This unbiased systems approach targeting connected nodes exemplifies a novel precision medicine strategy providing evidence that LSCs can be eradicated.
dc.languageEnglish
dc.publisherNATURE PUBLISHING GROUP
dc.titleDual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
dc.typeJournal Article
dc.identifier.doi10.1038/nature18288
melbourne.affiliation.departmentCentre for Cancer Research
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleNature
melbourne.source.volume534
melbourne.source.issue7607
melbourne.source.pages341-+
melbourne.elementsid1067028
melbourne.openaccess.urlhttps://europepmc.org/articles/PMC4913876?pdf=render
melbourne.openaccess.statusPublished version
melbourne.contributor.authorGrimmond, Sean
dc.identifier.eissn1476-4687
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record